[HTML][HTML] 免疫检查点抑制剂在PD-L1 低表达/阴性晚期NSCLC 患者中的治疗现状
赵坤， 苗健龙， 屈光义 - Advances in Clinical Medicine, 2023 - hanspub.org
… Non-small cell lung cancer is a type of cancer whose etiology and pathogenesis have …
immunotherapy in patients with low/negative PD-L1 expression in NSCLC and review the current …
immunotherapy in patients with low/negative PD-L1 expression in NSCLC and review the current …
[HTML][HTML] PD-L1 在非小细胞肺癌中的研究进展
苏晓梅， 严佳乐， 马晓梅 - Advances in Clinical Medicine, 2023 - hanspub.org
… Abstract: Non-small cell lung cancer (NSCLC) is a kind of lung … challenges, and only a
small number of NSCLC patients respond to ICIs, illustrating the need for better immunotherapy. …
small number of NSCLC patients respond to ICIs, illustrating the need for better immunotherapy. …
[HTML][HTML] PD-L1 检测方法在非小细胞肺癌的研究进展
郭雪晶， 曹赫， 周建娅， 周建英 - Chinese Journal of Lung Cancer, 2019 - ncbi.nlm.nih.gov
… -1/PD-L1抑制剂在非小细胞肺癌（non-small cell lung cancer, … In recent years,
immunohistochemistry (IHC) and enzyme-… PD-L1检测是Pembrolizumab的伴随诊断，肿瘤细胞表达…
immunohistochemistry (IHC) and enzyme-… PD-L1检测是Pembrolizumab的伴随诊断，肿瘤细胞表达…
PD-1/PD-L1 抑制剂疗效相关生物预测标记物的研究进展
董苑梅， 焦顺昌 - 解放军医学院学报, 2018 - xuebao.301hospital.com.cn
… the current progress and challenges of developing predictive biomarkers of immunotherapy
… Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer …
… Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer …
病理学指导下的非小细胞肺癌个体化免疫治疗
李媛 - 中国癌症杂志, 2020 - china-oncology.com
… 细胞肺癌(non-small cell lung cancer,NSCLC)组织中PD-L1的表达… (NSCLC): interim analysis
and biomarker data from a multicenter … The challenge of PD-L1 detection in the screening of …
and biomarker data from a multicenter … The challenge of PD-L1 detection in the screening of …
肿瘤突变负荷对PD-1/PD-L1 抑制剂治疗非小细胞肺癌临床疗效预测的Meta 分析
沈仕俊， 王巧丽， 杨金江， 李国剑， 李孟丽， 张小丽… - 肿瘤防治研究, 2021 - zlfzyj.com
… in non-small cell lung cancer treated by PD-1/PD-L1 inhibitors … of tumor mutation burden
as an immunotherapy biomarker: … : Major advancements and challenges[J]. J Immunother …
as an immunotherapy biomarker: … : Major advancements and challenges[J]. J Immunother …
[HTML][HTML] 非小细胞肺癌免疫治疗生物标志物的研究进展
黄川， 杨雪 - Chinese Journal of Lung Cancer, 2021 - ncbi.nlm.nih.gov
… type of lung cancer is non-small cell lung cancer (NSCLC). In … on predictive biomarkers for
immunotherapy of NSCLC and … 中47%患者PD-L1 TPS为50%或更高，而这部分PD-L1高表达的…
immunotherapy of NSCLC and … 中47%患者PD-L1 TPS为50%或更高，而这部分PD-L1高表达的…
中国非小细胞肺癌PD-L1 表达检测临床病理专家共识.
应建明， 王洁 - Chinese Journal of Oncology/Zhonghua …, 2020 - search.ebscohost.com
… on PD⁃L1 expression testing in non⁃small⁃cell lung cancer … issues regarding clinical
significance of PD⁃L1 testing, … of PD⁃L1 biomarker in non⁃small cell lung cancer[J]. Clin …
significance of PD⁃L1 testing, … of PD⁃L1 biomarker in non⁃small cell lung cancer[J]. Clin …
晚期非小细胞肺癌免疫治疗现状及未来方向
苏春霞， 周彩存 - 中国癌症杂志, 2022 - china-oncology.com
… , summarized the development of immunotherapy, discussed current problems, and …
pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor …
pembrolizumab versus chemotherapy for metastatic non-small cell lung cancer with PD-L1 tumor …
抗血管生成药物联合免疫检查点抑制剂治疗非小细胞肺癌的作用机制及临床应用进展
邱鲁鹏， 孙卓雅， 赵晓， 焦顺昌 - 解放军医学院学报, 2022 - xuebao.301hospital.com.cn
… immunotherapy has revolutionized the treatment of patients with non-small cell lung cancer
(NSCLC) in recent … PD-1/PD-L1 抑制剂作用于T 细胞的抑 制性通路,激活其对肿瘤细胞的免疫…
(NSCLC) in recent … PD-1/PD-L1 抑制剂作用于T 细胞的抑 制性通路,激活其对肿瘤细胞的免疫…